GRDN
Guardian Pharmacy Services, Inc.
GRDN's fundamentals are strong: free cash flow grew 47% and earnings per share grew 83%. At 42x earnings, it's trading below its usual 48x. Analysts expect that strong growth to continue.
GRDN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
GRDN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
GRDN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 34x | $49.38 | — |
| Current | 42x | $49.38 | — |
| Cheap | 44x | $51.74 | +4.8% |
| Fair | 48x | $56.09 | +14% |
| Expensive | 51x | $59.75 | +21% |
Historical ranges are pointers, not guarantees.
GRDN's PE is in its cheap range at 42x. If earnings grow as analysts expect, today's price would be 34x next year's earnings.
GRDN Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for GRDN, with profitability improving.
GRDN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.45 | +24% |
| Q3 2026 | $1.17 | +83% |
| Q2 2026 | $1.03 | +$2.54 |
| Q1 2026 | $0.83 | +$2.31 |
| Q4 2025 | $0.77 | +$2.54 |
| Q3 2025 | $0.64 | +$2.23 |
| Q2 2025 | -$1.51 | -786% |
| Q1 2025 | -$1.48 | -470% |
| Q4 2024 | -$1.77 | -411% |
GRDN earned $1.17 per share over the past year, up 83% from the year before.
GRDN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $371.1M | -1.7% |
| Q2 2026 | $351.8M | +2.2% |
| Q1 2026 | $336.6M | +2.2% |
| Q4 2025 | $397.6M | +17% |
| Q3 2025 | $377.4M | +20% |
| Q2 2025 | $344.3M | +15% |
| Q1 2025 | $329.3M | +20% |
| Q4 2024 | $338.6M | +20% |
GRDN's revenue is growing: $371M last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.8% | +2.3 points |
| Q2 2026 | 5.9% | +2.2 points |
| Q1 2026 | 5.3% | +1.3 points |
| Q4 2025 | 9.2% | +4.2 points |
| Q3 2025 | 4.5% | +38 points |
| Q2 2025 | 3.6% | -2 points |
| Q1 2025 | 4% | +1.1 points |
| Q4 2024 | 5% | -0.6 points |
GRDN's operating margin was 6.8% last quarter, up 2.3 points from the same quarter a year ago.
GRDN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $43.4M | +89% |
| Q2 2026 | $25.4M | +63% |
| Q1 2026 | $1M | -91% |
| Q4 2025 | $30.4M | +70% |
| Q3 2025 | $23M | +$30.3M |
| Q2 2025 | $15.6M | -40% |
| Q1 2025 | $11.7M | +137% |
| Q4 2024 | $17.8M | +51% |
GRDN generated $100M in free cash flow over the past year, up 47% from the year before.
GRDN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +80K shares |
| 1 year | +0.8% | +484K shares |
| 3 years | +5% | +3.1M shares |
| 5 years | +5% | +3.1M shares |
| Available history | +5% | +3.1M shares |
GRDN has 64M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $30.3M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $29M |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
GRDN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.5x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2024 | 1.4x | Healthy |
| Q1 2024 | -0.0x | Net Cash |
| Q4 2023 | 1.2x | Healthy |
GRDN has more cash than debt.
GRDN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.4 | Neutral |
| Stochastic | 60.9 | Neutral |
GRDN's weekly RSI is 67 (neutral) and its Stochastic is 61 (neutral).
GRDN PE vs Healthcare Sector
| Metric | GRDN | Sector median | Relative |
|---|---|---|---|
| PE | 42x | 26x | 63% above |
| PE % | 8 | 59 | 51 pts below |
GRDN is trading at 42x earnings, a 63% premium to the Healthcare sector's median of 26x.
GRDN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $42.0 | 17% above |
| 20 week MA | $41.3 | 20% above |
| 50 week MA | $37.5 | 32% above |
| 100 week MA | $30.3 | 63% above |
GRDN is in an uptrend: it's above all four of its weekly moving averages, and 63% above its 100-week average.
GRDN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $17.8 | $21.2 | +19% |
| 2025 | $21.2 | $30.7 | +45% |
| 2026 YTD | $30.7 | $49.4 | +61% |
GRDN has finished every year since 2024 higher, and it's up 61% so far in 2026.